CliffBio
small molecule

DAPTOMYCIN IN 0.9% SODIUM CHLORIDE

DAPTOMYCIN

Loss of exclusivity—loss of exclusivity
CompanyBaxter Healthcare Corp →See this company's full patent-cliff portfolio

Drug detail

Brand nameDAPTOMYCIN IN 0.9% SODIUM CHLORIDE
Active ingredientDAPTOMYCIN
Strength700MG/100ML (7MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalFebruary 2023
Marketing statusRX

More from Baxter Healthcare Corp

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.